Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
128 studies found for:    "CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
21 Not yet recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Conditions: Adenoid Cystic Carcinoma;   Adnexal Carcinoma;   Apocrine Carcinoma;   Eccrine Porocarcinoma;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Non-Melanomatous Lesion;   Paget Disease;   Papillary Adenocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage III Skin Cancer;   Stage IV Skin Cancer;   Sweat Gland Carcinoma;   Trichilemmocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 68
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02978625
22 Recruiting Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Stage 0-III Melanoma
Conditions: Stage 0 Skin Melanoma;   Stage I Skin Melanoma;   Stage IA Skin Melanoma;   Stage IB Skin Melanoma;   Stage II Skin Melanoma;   Stage IIA Skin Melanoma;   Stage IIB Skin Melanoma;   Stage IIC Skin Melanoma;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma
Interventions: Other: Internet-Based Intervention;   Other: Questionnaire Administration;   Other: Survey Administration
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Supportive Care
Number Enrolled: 420
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT03028948
23 Not yet recruiting Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Conditions: Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
Interventions: Drug: Abiraterone Acetate;   Drug: Androgen Receptor Antagonist ARN-509;   Biological: Gonadotropin-releasing Hormone Analog;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Radical Prostatectomy
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 90
Gender: Male
Age: Child, Adult, Senior
NCT Number: NCT02949284
24 Recruiting Talazoparib, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Metastatic Malignant Solid Neoplasm;   Unresectable Solid Neoplasm
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Talazoparib
Study Type: Interventional
Phase: Phase 1
Funder Type: NIH
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 66
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02317874
25 Recruiting Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Condition: Bladder Cancer
Interventions: Biological: TICE Bacillus Calmette-Guerin (BCG);   Biological: PANVAC
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH / Other
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 54
Gender: All
Age: 18 Years to 100 Years   (Adult, Senior)
NCT Number: NCT02015104
26 Recruiting Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Conditions: Stage II Non-Small Cell Lung Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Pembrolizumab
Study Type: Interventional
Phase: Phase 1
Funder Type: Other / NIH / Industry
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 30
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02621398
27 Recruiting Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy
Conditions: Stage 0 Breast Cancer;   Stage I Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Other: Internet-Based Intervention;   Other: Laboratory Biomarker Analysis;   Other: Survey Administration
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Supportive Care
Number Enrolled: 140
Gender: Female
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT03061175
28 Recruiting Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Conditions: Prostate Cancer;   Sexual Dysfunction and Infertility;   Sexuality
Interventions: Other: communication intervention;   Other: counseling intervention;   Other: nutrition intervention;   Other: questionnaire administration
Study Type: Interventional
Phase:
Funder Type: Other
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Masking: No masking;   Primary Purpose: Supportive Care
Number Enrolled: 372
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01982058
29 Recruiting Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Exposure: Adjuvant chemotherapy treatment;   Drug: Exposure: Adjuvant hormonal therapy treatment
Study Type: Observational
Phase:
Funder Type: Other
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Number Enrolled: 60
Gender: Female
Age: 20 Years to 70 Years   (Adult, Senior)
NCT Number: NCT02896504
30 Recruiting Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
Condition: Malignant Neoplasm
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Diagnostic
Number Enrolled: 1100
Gender: All
Age: 1 Year and older   (Child, Adult, Senior)
NCT Number: NCT02688517
31 Not yet recruiting A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
Conditions: Malignant Solid Tumor;   Metastatic Cancer;   Advanced Cancer
Interventions: Drug: RRx-001;   Drug: Irinotecan
Study Type: Interventional
Phase: Phase 1
Funder Type: Industry
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 24
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02801097
32 Recruiting Neurophysiological Evaluation of Training Effect on Cancer-Related Weakness
Condition: Breast Cancer
Interventions: Behavioral: Low Intensity Exercise Training 1;   Behavioral: Low Intensity Exercise Training 2
Study Type: Interventional
Phase:
Funder Type: Other / NIH / Industry
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Participant);   Primary Purpose: Treatment
Number Enrolled: 75
Gender: Female
Age: 50 Years to 75 Years   (Adult, Senior)
NCT Number: NCT02844504
33 Recruiting A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Condition: Prostate Cancer
Interventions: Biological: pTVG-AR;   Biological: gm-csf
Study Type: Interventional
Phase: Phase 1
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 40
Gender: Male
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02411786
34 Recruiting Phase I Study of Intratumoral CAVATAK™ and Pembrolizumab in Subjects With Advanced Melanoma
Condition: Melanoma
Interventions: Biological: CAVATAK;   Drug: Pembrolizumab
Study Type: Interventional
Phase: Phase 1
Funder Type: Industry
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 30
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02565992
35 Not yet recruiting Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
Conditions: Glioblastoma;   Oligodendroglioma;   Anaplastic Oligodendroglioma
Interventions: Drug: RRx-001 dose escalation with TMZ + RT;   Radiation: Radiation;   Drug: Fixed dose Temozolomide (75 mg/m2);   Drug: Fixed RRx-001 weekly;   Drug: Staged TMZ and RRx-001 escalation in maintenance stage;   Drug: TMZ Maintenance
Study Type: Interventional
Phase: Phase 1
Funder Type: Industry
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 39
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02871843
36 Recruiting Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Conditions: Mesothelioma;   Pleural Mesothelioma
Interventions: Drug: Concurrent Durvalumab;   Drug: Maintenance Durvalumab
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / Industry
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 55
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02899195
37 Recruiting A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Condition: Desmoid Tumor
Intervention: Drug: Sirolimus
Study Type: Interventional
Phases: Phase 1 / Phase 2
Funder Type: Other / Industry
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 15
Gender: All
Age: up to 29 Years   (Child, Adult)
NCT Number: NCT01265030
38 Recruiting Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors
Conditions: Advanced Malignant Solid Neoplasm;   Recurrent Malignant Solid Neoplasm
Interventions: Drug: Carboplatin;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide;   Drug: Trametinib;   Drug: Veliparib;   Drug: WEE1 Inhibitor AZD1775
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 700
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01827384
39 Recruiting Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
Condition: Brain Metastases
Intervention: Drug: RRx-001 + WBRT
Study Type: Interventional
Phase: Phase 1
Funder Type: Industry
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 30
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02215512
40 Recruiting Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: Proton Beam Therapy;   Radiation: Intensity Modulated Radiation Therapy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 400
Gender: Male
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01617161

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.